Page last updated: 2024-11-13
lycojapodine a
Description
lycojapodine A: isolated from Lycopodium japonicum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
lycojapodine A : An alkaloid isolated from the club moss Lycopodium japonicum and has been shown to exhibit acetylcholinesterase inhibitory and anti-HIV-1 activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Lycopodium | genus | A plant genus of the family LYCOPODIACEAE. Members contain ALKALOIDS. Lycopodium oil is obtained from L. clavatum.[MeSH] | Lycopodiaceae | The club-moss plant family of the order Lycopodiales, class Lycopodiopsida, division Lycopodiophyta, subkingdom TRACHEOPHYTA. The common name of clubmoss applies to several genera of this family. Despite the name this is not one of the true mosses (BRYOPSIDA ).[MeSH] |
| Lycopodium japonicum | species | [no description available] | Lycopodiaceae | The club-moss plant family of the order Lycopodiales, class Lycopodiopsida, division Lycopodiophyta, subkingdom TRACHEOPHYTA. The common name of clubmoss applies to several genera of this family. Despite the name this is not one of the true mosses (BRYOPSIDA ).[MeSH] |
Cross-References
Synonyms (6)
| Synonym |
|---|
| lycojapodine a |
| (-)-lycojapodine a |
| CHEBI:66603 |
| (5ar,6s,8r,9as)-8-methylhexahydro-9a,6-(epoxyethano)-1,5a-propano-1-benzazepine-5,11(2h)-dione |
| Q27135218 |
| (1r,2s,6s,16r)-16-methyl-5-oxa-7-azatetracyclo[5.4.3.32,6.01,6]heptadecane-4,11-dione |
Roles (3)
| Role | Description |
|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| EC 3.1.1.7 (acetylcholinesterase) inhibitor | An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid. |
| anti-HIV-1 agent | An anti-HIV agent that destroys or inhibits the replication of HIV-1, the more infective and more virulent of the two types of HIV virus. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (5)
| Class | Description |
|---|
| alkaloid | Any of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids. |
| lactone | Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. |
| cyclic ketone | |
| bridged compound | A polycyclic compound in which two rings have two or more atoms in common. |
| organic heterotetracyclic compound | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.84
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.84 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.63 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |